1187 studies on GLP-1 agonist class curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
This study provides crucial real-world evidence supporting the efficacy and safety of GLP-1 Receptor Agonists for managing Type 2 Diabetes in older adults, a population often underrepresented in initial clinical trial…
This comprehensive review underscores the critical role GLP-1 Receptor Agonists can play in managing Chronic Kidney Disease, moving beyond their traditional use in diabetes and obesity. The consistent evidence of sign…
This comprehensive review underscores that Semaglutide represents a significant therapeutic advancement, extending its benefits far beyond glucose control. Its dual cardioprotective and nephroprotective actions positi…
This research provides compelling evidence that GLP-1RAs possess direct antiarrhythmic properties, significantly extending their known cardiovascular benefits beyond glycemic control and weight loss. The observed subs…
This research underscores the chronic nature of obesity and highlights that GLP-1 receptor agonists function as effective long-term management tools rather than curative treatments. The rapid weight regain and metabol…
The patient presented with classic symptoms indicative of small bowel obstruction (SBO), including severe, colicky abdominal pain, persistent nausea, and intractable vomiting, leading to significant dehydration. Initi…
This research highlights the significant potential of GLP-1 receptor agonists as a novel pharmacological approach for treating Alcohol Use Disorder. The substantial reduction in alcohol intake and relapse-like behavio…
The findings from such a study are profoundly significant, as they suggest semaglutide could be more than just a weight-loss drug, offering a direct therapeutic benefit for obstructive sleep apnea. This represents a n…
This research provides novel insights into the neuroprotective mechanisms of Semaglutide, demonstrating its ability to combat obesity-linked neurodegeneration by modulating microglia activation and AD-like pathology t…
These findings provide crucial insights into the complex regulatory network within pancreatic islets, highlighting the dynamic and glucose-dependent role of δ cells in modulating α cell function. Understanding how gly…
This research provides crucial insights into the structural stability and aggregation mechanisms of semaglutide, which is vital for optimizing its formulation and storage. Understanding the pH-dependent formation of β…
These findings highlight FGF15 as a crucial endocrine factor that orchestrates beneficial adaptations in lean mass, bone, and bile acid metabolism during weight loss. The ability of exogenous FGF15 to mitigate the det…
This study provides crucial real-world data on the prevalence of hair shedding among GLP-1 RA users, definitively identifying rapid weight loss as a key contributing factor. Understanding this common side effect can h…
The study aimed to demonstrate that adding testosterone undecanoate could significantly enhance the therapeutic benefits for late responders to tirzepatide. While specific quantitative data is not available in the pro…
The development of these incretin-based medications marks a paradigm shift in obesity treatment, offering pharmacological options with efficacy levels previously only achievable through bariatric surgery. This advance…
This case report is crucial as it underscores the importance of careful and gradual insulin management when initiating potent glucose-lowering agents like tirzepatide. While tirzepatide is highly effective for glycemi…
This meta-analysis provides compelling evidence that weight loss is a critical determinant for reversing MASLD histological damage, offering a clear and actionable therapeutic target. The findings suggest that even mo…
This study provides compelling evidence that Tirzepatide could serve as a valuable adjunct therapy for overweight or obese individuals with Type 1 Diabetes, offering benefits beyond traditional insulin management. The…
Understanding the real-world adverse event profile of Tirzepatide and Semaglutide when used adjunctively in Type 1 Diabetes is critically important for both clinicians and patients. This information can help manage ex…
This study provides crucial evidence for the comparative effectiveness of next-generation incretin therapies, offering valuable insights for clinicians. The findings suggest that Tirzepatide may be the preferred choic…
This study provides crucial evidence that optimizing the use of highly effective glucose-lowering agents can lead to substantial long-term cost savings and significantly improved patient quality of life. The findings …
This study provides crucial real-world evidence supporting the use of GLP-1 RAs in solid-organ transplant recipients, a population often excluded from pivotal trials due to complex medical profiles. The superior effic…
This robust systematic review and meta-analysis provides compelling evidence that GLP-1 receptor agonists are highly effective in achieving MASH resolution and improving liver fibrosis, addressing a major unmet medica…
These findings provide crucial evidence for healthcare policy decisions and formulary inclusions, offering a global perspective on the economic value of modern diabetes treatments. Understanding the long-term economic…
This study highlights a significant and rapid shift in GLP-1 agonist utilization patterns, extending well beyond their primary indication for type 2 diabetes into the non-diabetic population. The substantial increase …
This study provides crucial evidence that tirzepatide, a dual GIP/GLP-1 receptor agonist, offers superior cardiovascular protection compared to the established GLP-1 receptor agonist dulaglutide in patients with type …
This research provides invaluable, patient-centered insights that are crucial for optimizing the development, prescription, and long-term success of obesity pharmacotherapies. Understanding these deeply personal prefe…
This study highlights the critical challenge of maintaining weight loss after discontinuing potent anti-obesity medications like Semaglutide and Tirzepatide in a real-world clinical setting. It underscores the need fo…
This comprehensive network meta-analysis provides crucial evidence that Tirzepatide may be the most efficacious pharmacological option for weight management in individuals with obesity who do not have Type 2 Diabetes.…
This comprehensive meta-analysis solidifies the role of GLP-1 receptor agonists as highly effective pharmacological interventions for obesity management, providing strong evidence for their widespread clinical adoptio…
This study provides compelling real-world evidence that Tirzepatide, a dual GLP-1 and GIP receptor agonist, may offer superior neuroprotection compared to semaglutide (a GLP-1 receptor agonist) in patients with type 2…
This study highlights ARD-101 as a promising novel therapeutic strategy for obesity and metabolic disorders, leveraging a gut-restricted mechanism to potentially minimize systemic side effects. The synergistic effect …
This case report highlights a critical, albeit rare, adverse event associated with tirzepatide use in non-diabetic individuals seeking weight loss. It underscores the importance of clinician awareness regarding the po…
This comprehensive scoping review provides compelling evidence that GLP-1 receptor agonists and Tirzepatide are not just effective for glycemic control and weight management, but also offer substantial and consistent …
This case report highlights a critical safety concern for patients on tirzepatide and SGLT-2 inhibitors, emphasizing the importance of patient education regarding 'sick-day rules.' The finding that these agents can be…
This joint guidance statement represents a significant step forward in standardizing and optimizing the pharmacological management of overweight and obesity in the United States. By providing clear, evidence-based rec…
This comprehensive review provides crucial guidance for clinicians and patients regarding the safe and effective use of GLP-1 RAs in individuals of reproductive age. It underscores the critical need for thorough couns…
This real-world evidence strongly suggests that Tirzepatide may offer significant cardiovascular protection beyond its established metabolic benefits, even in patients without diabetes. The observed reduction in recur…
This meta-analysis provides compelling evidence that Tirzepatide, a dual GIP/GLP-1 receptor agonist, offers significant therapeutic potential for patients with HFpEF. The observed improvements in weight, glycemic cont…
This study highlights a critical concern: while GLP-1 receptor agonists are highly effective for weight loss, the potential for significant lean muscle mass loss needs careful consideration. Preserving muscle is vital…
This 2026 Update provides crucial, up-to-date, and evidence-based recommendations that will significantly impact the clinical management of MASLD and MASH globally. By clearly outlining the efficacy of various pharmac…
This post-hoc analysis highlights the critical importance of early treatment response as a predictor of overall success with tirzepatide and semaglutide for obesity. The findings suggest that monitoring early weight l…
The profound influence of social media on public health discourse and patient behavior is a critical concern, particularly for highly sought-after medications like GLP-1 RAs. This research underscores an urgent need f…
These findings suggest that tirzepatide could be a transformative treatment for the severe metabolic complications associated with Partial Lipodystrophy, a condition with limited effective therapies. By simultaneously…
This systematic review highlights a novel and potentially impactful therapeutic avenue for patients suffering from Hidradenitis Suppurativa, particularly those with underlying metabolic comorbidities. Repurposing exis…